Data will be shared in two oral presentations, a poster and two online abstractsHighlights include a potential novel, ...

Clear signs of immune activation: ICT01 at the 10 mg dose provided optimal activation of γ9δ2 T cells and a downstream immune ...

Earlier this year, Cullinan said its lead candidate hit the bull's-eye in a midstage lung cancer cancer trial but stayed mum ...

Jail terms for a Melbourne music teacher who filmed himself sexually violating children and his fiance who fantasised about the victims being raped have been reduced on appeal.

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

To provide updated guidance regarding neoadjuvant chemotherapy (NACT) and primary cytoreductive surgery (PCS) among patients with stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal ...

Be among those who shape the future with knowledge. Uncover exclusive stories that captivate your mind and heart with our ...

Cullinan Management, Inc. ( ($CGEM) ) has released its Q1 earnings. Here is a breakdown of the information Cullinan Management, Inc. presented to ...

In its 15th year, Verastem Oncology has gained its first FDA approval, winning an accelerated nod for the combination treatment of avutometinib and defactinib for a rare form of ovarian cancer.

Zipalertinib (EGFR ex20ins inhibitor), collaboration with Taiho Oncology: EGFR ex20ins NSCLC In January 2025, Cullinan announced that the pivotal Phase 2b portion of REZILIENT1 met the primary ...

The FDA’s Oncologic Drugs Advisory Committee (ODAC) is planning to host its first meeting under new agency commissioner Marty Makary, M.D. As head of the FDA’s oncology department, Richard ...